

1 10 20 30 40 50
VH1-69/JH4 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGG
mu8D6 VH QVQLQQSGAELAKPGASVMLSCKASGYTFNGYWMHWVKQRPGQDLEWIGY
hu8D6 VH QVQLVQSGAEVKKPGSSVKVSCKASGYTFNGYWMHWVRQAPGQGLEWIGY
51a 60 70 80 abc 90
VH1-69/JH4 IIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCAR--
mu8D6 VH INPTTGHTEYNQKFKDKATLTADESSNTAYIELSSLTSDDSAVYYCARQE
hu8D6 VH INPTTGHTEYNQKFKDKATITADESTNTAYMELSSLRSEDTAVYYCARQE
100 110
VH1-69/JH4 ----YFDYWGQGTLVTVSS (SEQ ID NO: 11)
mu8D6 VH YRHSWFAYWGQGTLVTVSA (SEQ ID NO: 1)
hu8D6 VH YRHSWFAYWGQGTLVTVSS (SEQ ID NO: 2)

FIG. 1

```
                  1         10         20       abcd 30          40
Vκ1-39/Jκ1        DIQMTQSPSSLSASVGDRVTITCRASQSIS----SYLNWYQQKPGKAPKL
mu8D6 Vκ          DIVLTQSPASLAVSLGQRATISCKASQSVDYDGDTYMNWYHQKPGQPPKL
hu8D6 Vκ          DIQLTQSPSSLSASVGDRVTITCRASQSVDYDGDTYMNWYQQKPGKAPKL
                     *
                     50         60         70         80          90
Vκ1-39/Jκ1        LIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQS-YSTW
mu8D6 Vκ          LIYAASNLDSGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQTNEDPW
hu8D6 Vκ          LIYAASNLDSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQTNEDPW

                     100      107
Vκ1-39/Jκ1        TFGQGTKVEIKR (SEQ ID NO:12)
mu8D6 Vκ          TFGGGTKLEIKR (SEQ ID NO: 3)
hu8D6 Vκ          TFGQGTKVEIKR (SEQ ID NO: 4)
```

FIG. 2



hu8D6
c8D6
OD450
3.0
2.5
2.0
1.5
1.0
0.5
0.0
10-8
10-7
10-6
10-5
10-4
10-3
10-2
10-1
Ab conc. (mg/ml)

FIG. 3



hu8D6
c8D6
OD450
3.0
2.5
2.0
1.5
1.0
0.5
0.0
10-7
10-6
10-5
10-4
10-3
10-2
10-1
100
Ab conc. (mg/ml)

FIG. 4



25 nM
12.5 nM
6.25 nM
3.12 nM
K_{on}
K_{off}
RU
300
250
200
150
100
50
0
-50
0
200
400
600
800
1000
Time (s)

FIG. 5



hu8D6
c8D6
Geometric Mean Intensity
Ab conc. (mg/ml)

FIG. 6b



hu8D6
c8D6
Geometric Mean Intensity
Ab conc. (mg/ml)

FIG. 6a



OD450
2.0
1.5
1.0
0.5
0.0
10
1
0.1
0.01 μg/ml
human IgG
hu8D6
c8D6
Omalizumab
5H2

FIG. 7




FIG. 8a

FIG. 8b

FIG. 8c




FIG. 8e




FIG. 8d



hu8D6
Omalizumab
Trastuzumab
OD450
2.5
2.0
1.5
1.0
0.5
0.0
10-8
10-6
10-4
10-2
100
Ab conc. (mg/ml)

FIG. 9



hu8D6
Omalizumab
Trastuzumab
Geometric Mean Intensity
40
30
20
10
0
10^{-1}
10^{0}
10^{1}
10^{2}
Ab conc. (μg/ml)

FIG. 10



% of β-hexosaminidase release
0
10
20
30
40
50
60
70
80
hIgG
c8D6
hu8D6
Omalizumab
5H2
10
1
0.1
0.01
µg/ml

FIG. 11



10
1
0.1
0.01
μg/ml
OD450
2.0
1.5
1.0
0.5
0.0
human IgG
c8D6
hu8D6
Omalizumab
5H2

FIG. 12




FIG. 13b




FIG. 13a




FIG. 13d




FIG. 13c




FIG. 14a

FIG. 14b

FIG. 14c




FIG. 14e




FIG. 14d



Omalizumab:IgE
hu8D6:IgE
c8D6:IgE
5H2:IgE
hIgG:IgE
0
10
20
30
40
50
60
70
80
% of β-hexosaminidase release

FIG. 15




FIG. 16b




FIG. 16a




FIG. 16d




FIG. 16c



Omalizumab
Day 7
P=0.1139, N=5
Day 11
P=0.0249, N=7
Day 14
P=0.0313, N=8
ng / ml
600
500
400
300
200
100
0
Tasliuzumab
Omalizumab

FIG. 17a



hu8D6
Day 7
P=0.0376, N=5
Day 11
P=0.0094, N=7
Day 14
P=0.0077, N=8
ng / ml
0
100
200
300
400
500
600
Taslizumab
hu8D6

FIG. 17b